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Herpes simplex virus type-1 and -2 (HSV-1 and -
2) can produce acute and latent infections in humans
and in experimental animals (1). After infection,
HSV replicates at the inoculation site and then
migrates along rachydeal and autonomic nerves
towards the nuclei of neurons (2-3), where it induces
a life-long latent infection. Cell-mediated and
humoral immunity have been reported to play key
roles in the defense against HSV infection.
Immunocytochemical studies in skin biopsies taken
from patients with recurrent HSV infections showed
infiltration of T lymphocytes around the necrotic
lesions (4) and clearance of HSV-2 from recurrent
genital lesions has been associated with the local
activity of CD4+ T and CD8+ T cells (5). In addition,
HSV-1 neurovirulence was enhanced in vivo when
animals were treated with antibodies against anti-
CD8+ T lymphocytes (6). 
It has been reported that HSV-1 uses several
strategies to evade or subvert the immune response
(7-9). Viral protein ICP47 has been reported to bind
the transporter associated with antigen processing
(TAP), thus blocking presentation of viral peptides
to major histocompatibility complex class-I-
restricted cells (10). Furthermore, HSV-1
glycoprotein D has been reported to inhibit T-cell
proliferation through the inhibition of signaling
pathways triggered by the herpes virus entry
mediator HVEM (11). After infection with HSV-1,
antigen-presenting cells are also impaired in their
ability to induce CD4+ T cell activation (12).
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Apoptosis of cytotoxic T lymphocytes by herpes simplex virus type-1 (HSV-1) has been reported to
be a relevant mechanism of viral immune evasion. Galectin-1 (Gal-1), an endogenous lectin involved in
T-cell apoptosis, has recently gained considerable attention as a novel mechanism of tumor-immune
evasion. Here we investigated whether infection of cells with HSV-1 can modulate the expression of Gal-
1. Results show that pro-apoptotic Gal-1, but not Gal-3, is remarkably up-regulated in cell cultures
infected with HSV-1. In addition, this protein is secreted to the extracellular milieu, where it contributes
to apoptosis of activated T cells in a carbohydrate-dependent manner. Since many viruses have evolved
mechanisms to counteract the antiviral response raised by the infected host, our results suggest that
HSV-1 may use galectin-1 as a weapon to kill activated T cells and evade specific immune responses.
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Furthermore, fraticidal cell death of T lymphocytes
has been proposed to be an important immune
evasion mechanism following HSV-1 infection,
favoring the persistence of the virus in the host
throughout its lifetime (13). However, the molecular
mediators and biochemical pathways involved in
HSV-1-induced apoptosis have not yet been
elucidated in detail. It has been demonstrated that
following 1 h infection of epithelial cells, HSV-1 can
trigger the synthesis of proteins involved in cellular
apoptosis, whereas after 3-6 h post-infection cells
start to synthesize a number of proteins which can
block the process of cell death (14). Early viral
genes are immediately involved in this subtle
regulation of promotion and inhibition of apoptosis
(15), whereas NF-kappa B (16) and Us3 viral protein
kinase (17) are required for apoptosis prevention. In
this sense, it has been speculated that HSV-1-
infected epithelial cells induce apoptosis of
cytotoxic T lymphocytes (CTLs) to avoid immune
attack. In fact, recent studies demonstrated the
inactivation of CTLs after cell-to-cell contact
between CTLs and HSV-infected cells (18). 
Galectins are members of a large, growing family of
endogenous animal lectins which share sequence
similarities in the carbohydrate recognition domain
(CRD) and specificity for β-galactoside-containing
saccharide ligands (19-21). Despite extensive sequence
homology and similarities in sugar-binding specificity,
various members of this protein family (such as
galectin-3) behave as amplifiers of the inflammatory
response and protect cells from apoptosis, while others,
such as galectin-1 (Gal-1), have pro-apoptotic and
immunosuppressive activity (22-26).
Recently, we have reported that targeted
inhibition of Gal-1 gene expression in the tumor
microenvironment suppresses tumor growth and
results in heightened T cell- mediated rejection (27),
providing evidence of a novel mechanism by which
tumor cells evade immune attack (28).  Furthermore,
we have also reported the ability of Gal-1 and Gal-3
to modulate the outcome of Trypanosoma cruzi
infection by influencing macrophage and B-cell
survival (29-30). In addition, Kiss and colleagues
reported the up-regulation of galectin-3 and its
ligands following T. cruzi infection, an effect which
was associated with modulation of adhesion and
migration of murine dendritic cells (31). These
results suggest that galectins might be important in
the control of intracellular infections. Recently,
Lanteri and colleagues (32) showed that in vitro
infection of T cell lines with human immunodeficiency
virus type-1 (HIV-1) increases the levels of core 2-O
glycans, which constitute the preferred ligands for
Gal-1, suggesting a potential role for this pro-
apoptotic protein in the context of viral infections. 
In the search for potential mediators involved in
HSV-1-induced T-cell death and immunosuppression,
we investigated Gal-1 expression and function after
infection of epithelial cells in vitro with HSV-1.
MATERIALS AND METHODS
Virus and cells
The MacIntyre strain of HSV-1 was used. The virus
was obtained from the Center for Diseases Control
(Atlanta, GA), cultured in Vero cells and titrated by the
classic plaque-forming units method. 
Indirect immunofluorescence
Vero cells (obtained from the National Institute for
Microbiology, Argentina) were grown onto glass
coverslips placed into Petri dishes with Dulbecco’s
modified Eagle medium (DMEM) (Gibco) and 10% fetal
calf serum, at 37ºC and with an atmosphere of 5% CO2
Coverslips were fixed in methanol and rehydrated in PBS.
Non-specific background was blocked by the addition of
5% normal goat serum in PBS. The first antibodies were
either rabbit IgG anti-HSV-1 (Dako) diluted in PBS 1:500
or rabbit anti-Gal-1 or anti Gal-3 polyclonal Abs diluted
1:100 in PBS prepared as described (26). After washing,
the secondary antibody (goat anti-rabbit IgG-TRICT
conjugated) was added at a dilution of 1:100 in PBS.
SDS-PAGE and Western blot analysis 
Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) was performed in a
Miniprotean-II electrophoresis apparatus (Bio-Rad). Non-
infected or HSV-1-infected Vero cells were collected in
PBS, centrifuged and resuspended in 100  ml of ice-cold
lysis buffer containing a protease inhibitor cocktail
(Sigma Chemical Co.). Serum-free conditioned medium
(SFCM) from non-infected and HSV-1-infected cells
were also collected and concentrated by overnight
precipitation with 9 vol. of methanol at -20°C in order to
investigate the levels of Gal-1 secretion
Protein concentration was measured using the Micro-
BCA kit (Pierce). Equal amounts of protein (30 µg) of cell
lysates obtained from non-infected or HSV-1-infected
cells were loaded into each lane of the gel. Samples were
electrophoresed in a 15% separating polyacrylamide slab
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gel, transferred onto nitrocellulose membranes and
probed with a 1:1000 dilution of the anti-Gal-1 or anti-
Gal-3 polyclonal antibodies. Blots were then incubated
with a 1 mg/ml concentration of horseradish peroxidase-
conjugated anti-rabbit IgG, developed using the ECL
detection reagent (Amersham Pharmacia) and exposed to
Amersham Hyperfilm for 3 to 5 min. Equal loading was
checked by Ponceau S staining or by incubation of the
blots with an anti-a tubulin mAb (Sigma).A
Apoptosis assays 
Peripheral blood mononuclear cells (PBMCs) were
isolated from healthy human volunteers by Ficoll-
PaqueTM Plus gradient centrifugation, washed and
resuspended in RPMI 1640 supplemented with 10%
heat-inactivated, pooled normal human AB serum,
sodium pyruvate, glutamine and penicillin-streptomycin
(RPMI/PHS). PBMCs were stimulated with anti-CD3
mAb to activate T cells, and cultured for 3 days in 24-
well, microtiter plates. Fully activated T cells (as
measured by the levels of CD69 and CD25 expression)
were then exposed for 18 h to supernatants obtained
from HSV-1-infected or non-infected Vero cells and
processed for apoptosis. To rule out the possibility that
HSV-1 may directly interact with human lymphocytes,
we added a specific anti-HSV-1 serum to the culture
medium to neutralize eventual infectious viral particles.
To determine whether HSV-1-induced T-cell apoptosis
involved a Gal-1-mediated pathway, activated T cells
were also exposed to HSV-1-infected or non-infected
cells in the presence of thiodigalactoside (TDG, 30
mM), or a blocking anti-Gal-1 antibody (10 µg/ml) as
described (27). Cells exposed to different treatments
were finally processed for apoptotic cell detection by
propidium iodide (PI) (Sigma Chemical Co.) staining of
subdiploid nuclei or by annexin V staining using the
FITC -annexin V binding assay (BD Biosciences).
Statistical analysis
Comparison of two groups was made using Student´s t
test for unpaired data in apoptosis assays. P<0.05 was
considered statistically significant.
RESULTS
In vitro infection with HSV-1 up-regulates the
synthesis and secretion of Gal-1 
To investigate the role of Gal-1 during HSV-1
infection, we explored whether the in vitro infection
with HSV-1 is sufficient to modulate expression of
pro-apoptotic Gal-1 in target cells. Monolayers of
Vero cells were grown onto glass coverslips and
infected at a M.O.I. of 1 pfu of HSV-1/cell. After 2
h of adsorption, cells were washed with PBS and
fresh medium was added. At 18 h post-infection (pi)
the coverslips were fixed and processed for indirect
immunofluorescence (IFI). Fig. 1 illustrates (i): non-
infected Vero cells (A) and HSV-1-infected cells (D)
treated with normal rabbit serum as primary
antibody; (ii): non-infected (B) and HSV-1-infected
(E) cells stained with an anti-HSV-1 serum; and (iii):
non-infected (C) and HSV-1-infected monolayers
(F) treated with an anti-Gal-1 antibody. A productive
infection was clearly detected at 18 h p.i. (E). A
dramatic up-regulation of Gal-1 expression was
found in HSV-1-infected (F) versus non-infected
Vero cells (C). Up-regulated expression of Gal-1
was also observed following infection of human
fibroblasts with HSV-1 (data not shown). 
In another set of experiments, Vero cells
monolayers were infected as described above,
harvested after 18 h p.i and processed for Western
blot analysis. As shown in Fig. 2A, Gal-1 levels
were markedly increased in Vero cells after infection
with HSV-1 for 18 h (lane 1) as compared with
uninfected cells (lane 2). In addition, Gal-1 was also
present in concentrated supernatants from HSV-1-
infected cells (Fig. 2B, lane 1), but not in uninfected
Vero cells (Fig. 2B, lane 2), suggesting that HSV-1
induces release of Gal-1 from infected target cells to
exert extracellular biological functions.  In contrast,
lower levels of Gal-3 were found by Western blot
analysis in uninfected Vero cells (Fig. 2C; lane 2)
and its expression was not affected after productive
infection with HSV-1 for 18 h under the
experimental conditions used (Fig. 2C, lane 1). 
Herpes simplex virus-1-infected cells promote T-
cell apoptosis through a Gal-1-dependent pathway 
To gain insights into the functional significance of
up-regulated Gal-1, optimal dilutions of supernatants
(serum-free conditioned medium: SFCM) from HSV-
1-infected or uninfected cells were collected and
added to anti-CD3-stimulated T cells (at a 1:10
dilution) to evaluate HSV-1-induced T-cell apoptosis
in the absence or presence of thiodigalactoside (TDG;
a galectin-specific carbohydrate inhibitor) or a
blocking anti-Gal-1 antibody.
As shown in Fig. 3, SFCM derived from HSV-1-
infected cells induced high levels of apoptosis
(50.17%) on anti-CD3 mAb-stimulated T cells
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(upper left panel), as shown by propidium iodide
(PI) staining of subdiploid DNA content. In contrast,
lower levels of apoptosis (24.09 %) were detected in
anti-CD3 mAb-stimulated T cells cultured in the
presence of SFCM derived from non-infected Vero
cells (Fig. 3, second left panel). The pro-apoptotic
activity displayed by supernatants from HSV-1-
infected cells was partially abrogated when SFCM
was preabsorbed with 30 mM TDG (Fig. 3, upper
right panel; 19.96%) or a blocking anti-Gal-1
antibody (10 µg/ml) (Fig. 3, lower left panel;
18.76%) before exposure to stimulated T cells
suggesting that the pro-apoptotic effect was at least
in part associated to the release of biologically active
Gal-1 and that the carbohydrate-binding properties
of this lectin are involved in this process. As a
control, no significant changes in the levels of
apoptosis were detected when supernatants from
non-infected cells were incubated in the presence of
TDG or an anti-Gal-1 antibody before exposure to
anti-CD3 mAb-stimulated T cells (Fig. 3, second
and lower right panels respectively).  As a negative
control, anti-CD3 mAb-stimulated T cells, which
were cultured for 18 h in the absence of any other
Fig. 1. Immunodetection of Gal-1 by indirect immunofluorescence staining in mock-infected and HSV-1-infected Vero
cells. The figure shows an indirect immunofluorescence staining of non-infected (A, B, C) and HSV-1-infected (D, E, F)
Vero cells at 18 h pi. For control purposes, non-infected (A) and HSV-1-infected (D) were incubated with normal rabbit
serum as primary antibody. To determine productive infection, non-infected (B) or HSV-1-infected cells (E) were also
stained with specific anti-HSV-1 antibody. To analyze modulation of Gal-1 expression, non-infected (C) and HSV-1-
infected cells (F) were exposed to a rabbit anti-human Gal-1 polyclonal antibody. The productive infection due to HSV-
1 was evident at 18 h p.i (E) compared with the absence of labeling in non-infected cells (B). 
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stimuli showed low levels of apoptosis (~7-8%)
(data not shown).  Similar biologically and
statistically significant differences were observed
when T-cell death was analyzed by annexin V
staining (Fig. 3B). 
Taken together, these results indicate that HSV-1
modulates expression and secretion of cellular Gal-1
after productive infection in vitro, while it does not
affect expression of Gal-3, another member of the
galectin family with mainly pro-inflammatory
activity. Moreover, supernatants from HSV-1-
infected cells display pro-apoptotic activity, which
was dependent on the carbohydrate-binding
properties of this protein. These combined results
suggest that up-regulation of Gal-1 may account, at
least in part, for augmented T-cell apoptosis
observed following HSV-1 infection.
DISCUSSION
Viruses have evolved several strategies to
counteract the antiviral immune responses raised by
the infected host. These strategies include blockade
of components of the antigen processing machinery,
inhibition of pro-inflammatory cytokines and
induction of T-cell apoptosis (7-9). 
Recent studies indicated that tumors can evade T
cell mediated responses through Gal-1-dependent
mechanisms (27). Interestingly, inhibition of Gal-1
gene expression in tumor tissues resulted in reduced
tumor growth and enhanced T cell mediated
rejection, suggesting a role for this protein as a novel
factor implicated in tumor-immune evasion. The
association between these observations and the role
of T cell apoptosis as a relevant mechanism of
evasion during HSV-1 infection, prompted us to
investigate the regulated expression of Gal-1 during
HSV-1 infection and its contribution to T cell death. 
Galectins have recently gained considerable
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Fig. 2. Western blot analysis of Gal-1 and Gal-3 in total cell extracts and serum-free conditioned medium from non-infected
and HSV-1 infected Vero cells. Herpes simplex virus-1 specifically up-regulates Gal-1 expression (panel A; lane 1 vs lane 2)
and induces Gal-1 secretion (panel B, lane 1 vs lane 2) from infected Vero cells, while does not affect Gal-3 expression (panel
C, lane 1 vs lane 2). Briefly, cells were infected with HSV-1 as described in Materials and methods. After 18 h, mock infected
and HSV-1-infected cells were extensively washed to remove extracellular viral particles and lysates were prepared and
processed for Western blot analysis. To determine modulation of Gal-1 and Gal-3 expression, equal amounts of proteins (30
µg) of each cell extract were loaded into each lane, blotted onto nitrocellulose membranes and revealed using rabbit anti-
Gal-1 (panel A) or anti-Gal-3 (panel C) specific polyclonal antibodies. Equal amounts of protein were checked using an anti
α-tubulin monoclonal antibody (Sigma). To investigate Gal-1 secretion, serum-free supernatants from mock-infected or HSV-
1-infected cells were also collected, concentrated and processed by Western analysis (panel B). Gal-3 secretion was not
observed in supernatants from mock infected or HSV-1-infected cells under the sensitivity of this method (data not shown). 
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attention as novel regulator of T cell homeostasis.
Gal-1 has been shown to impair T cell effector
functions by promoting growth arrest and apoptosis
of activated T cells (25, 33-34), antagonizing T-cell
activation (35) and/or blocking pro-inflammatory
cytokine secretion (24,36). In vivo, therapeutic
administration of Gal-1 suppresses T helper (TH)-1-
dependent chronic inflammation in experimental
models of autoimmunity by increasing T-cell
susceptibility to activation-induced cell death and
skewing the balance of the immune response towards
a TH2 profile (26,37). Since HSV-1 has been shown to
subvert immune responses by inhibiting T-cell
survival and proinflammatory cytokine secretion (7-
9), this infection provides an excellent opportunity to
correlate the levels of Gal-1 with the outcome of the
infection. Studies are currently being conducted in
our laboratory to examine the progression of
experimental infections in Gal-1-null mutant mice.
Our results indicate that after the infection of
epithelial cells with HSV-1, Gal-1 synthesis is
remarkably increased. Moreover, this protein is also
secreted to supernatants of infected cells. Release of
biologically active Gal-1 to culture medium of HSV-
1-infected cells was clearly associated with an
induction of apoptosis of human activated T
lymphocytes. Participation of a Gal-1-mediated
mechanism in this apoptotic effect was confirmed,
since it could be inhibited by addition of TDG (a β-
galactoside-related sugar) or a blocking anti-Gal-1
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Fig. 3. Supernatants from HSV-1-infected cells induce apoptosis of activated T cells through a Gal-1-dependent pathway.
Peripheral blood mononuclear cells were activated with anti-CD3 monoclonal antibody for three days as described in
Materials and methods to mimic peptide-MHC cross-linking of the TCR/CD3 complex. Fully activated T cells were
further exposed for 18 h to supernatants derived from HSV-1-infected (upper left panel) or non-infected (second left
panel) Vero cells, in the absence or in the presence of 30 mM thiodigalactoside (TDG), a specific galectin inhibitor
(upper right panel) or a blocking anti-Gal-1 antibody (10 µg/ml; lower left panel). Apoptosis was then assessed by
analyzing the frequency of cells with subdiploid nuclei using propidium iodide (PI) staining (A) or by measuring the level
of phosphatidilserine exposure using FITC-anexin V (B) as described in Materials and methods. As a control, anti-CD3
mAb-stimulated T cells cultured for 18 h in the absence of any other stimuli showed low levels of apoptosis (~ 7-8%).
Similar results were obtained after T-cell activation with PHA instead of an anti-CD3 mAb. Data are representative of
three independent experiments using T cells from different donors. *P<0.05 supernatants from HSV-infected vs
supernatants from mock infected cells; **P<0.05 supernatants of HSV-1-infected cells cultured in the presence of TDG
or anti-Gal-1 vs supernatants of HSV-1-infected cells cultured in the absence of anti-Gal-1 antibody or TDG.
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antibody to the culture medium. These results were
not due to the direct effects of HSV-1 interaction
with human lymphocytes since a specific anti-HSV-
1 serum had been added to the culture medium to
neutralize any eventual infectious viral particles.
Moreover, we also rule out the possibility that Gal-1
present in the serum added to the culture medium
could be responsible of the effects described, since
serum-containing medium was replaced by serum-
free medium after viral adsorption to the cells.
Furthermore, according to our results, it is evident
that HSV-1 infection dramatically increases Gal-1
expression, while the synthesis of Gal-3 is not
significantly affected in comparison with non-
infected cells, suggesting the ability of HSV-1 to
specifically modulate Gal-1 gene expression. The
intracellular pathways involved in this regulated
expression are currently under investigation. 
The multivalent properties of galectins make these
proteins suited for cell adhesion functions, suggesting
that they could also be engaged in host-pathogen
interactions. In fact, β-galactoside-related
carbohydrates (polygalactose epitopes) are commonly
present in pathogen-associated glycoconjugates
leading to the suggestion that galactose-binding
proteins may act as host receptors for bacteria, fungi
and parasites and there are now several examples in
the literature of apparent direct or indirect galectin-
dependent specific host-pathogen interactions
(reviewed in 38).   For example, Moddy et al (39)
demonstrated that galectin-3 specifically binds to T.
cruzi trypomastigotes and modulates adhesion of the
parasite to extracellular matrix glycoproteins, such as
laminin in a carbohydrate-dependent manner (39).
Furthermore, Sato and colleagues (40-41) showed that
galectins-3 and -9 can interact with Leishmania major
through binding to specific polygalactose epitopes on
lipophosphoglycans (LPG) and galectin-1 can favor
attachment of HIV-1 to target cells (42). In agreement
with these findings, recent work showed that [GalNAc
β1-4GlcNAc] (LacdiNAc)-glycans constitute a
specific parasite pattern for galectin-3-mediated
immune recognition (43). Thus, galectins may
function as potential pattern recognition receptors (or
danger signals) transmitting the information of
microbial invasion to immune cells. 
To conclude, in the present study we describe the
up-regulation of Gal-1 after in vitro lytic infection of
cells with HSV-1.  Furthermore, HSV-1 induces
release of bioactive Gal-1 from epithelial cell
cultures, which contributes to apoptosis of activated
T cells. Although these results cannot be
extrapolated “prime facie” to the situation of the
natural infection produced by HSV-1 in humans, it is
attractive to hypothesize that during the acute phase
of HSV-1 infection, the virus may trigger a Gal-1-
mediated immunosuppressive effect towards
effector T lymphocytes using a novel, but
evolutionarily conserved, immune evasion
mechanism, as has been proposed for tumour cells.
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